Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al
Ann Rheum Dis. 2022 Aug 11;81(9):e185.
doi: 10.1136/annrheumdis-2020-218686.
1 Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany [email protected].
2 Praxiszentrum St. Bonifatius Muenchen, Muenchen, Germany.
3 Department of Rheumatology, Clinical Immunology and Osteology, Munich Clinic Bogenhausen, Munich, Germany.
4 Department of Rheumatology, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany.
5 Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany.